https://www.leukaemia.org.au/news/msac-advising-on-cilta-cel-car-t-cell-therapy-for-myeloma/
MSAC advising on cilta-cel CAR T-cell therapy for myeloma
Mar 20, 2026 - Explore cilta-cel CAR T-cell therapy and its potential to treat refractory multiple myeloma through innovative cell modification.
car t cell therapymsacadvising
https://www.ciltapd.com.au/course_provider/auditor-training-global/
CILTA Centre for Professional Development Course Providers Auditor Training Global
for professionaldevelopment courseauditor trainingcentreproviders
https://deceraclinical.com/education/activities/oncology/cartitude-4-with-cilta-cel-vs-soc/17431-25050/info
CARTITUDE-4: Phase III Trial of Cilta-Cel vs SoC for Lenalidomide-Refractory Multiple Myeloma |...
Phase III CARTITUDE-4 study evaluating cilta-cel vs standard of care in lenalidomide-refractory MM, presented at ASCO 2023 and reported by Clinical Care...